Drug Profile
Research programme: rho-associated protein kinase-2 inhibitors - HitGen
Alternative Names: ROCK2 inhibitors - HitGenLatest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator HitGen
- Class Antiglaucomas; Antihypertensives; Antineoplastics; Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Glaucoma; Liver cancer; Non-small cell lung cancer; Pulmonary arterial hypertension
Most Recent Events
- 28 Apr 2021 No recent reports of development identified for research development in Glaucoma in China (PO)
- 28 Apr 2021 No recent reports of development identified for research development in Liver-cancer in China (PO)
- 28 Apr 2021 No recent reports of development identified for research development in Non-small-cell-lung-cancer in China (PO)